Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1357874 · FYE May 21 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $7.00Day +1.60%Mkt cap $181M1Y +45.8%Off 52W high −27.2%Vol (1Y) 70.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,840 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.2% of sh out |
| Days to cover3.6d |
| 13F net flow (QoQ)+0.73% |
| Top-10 13F concentration80.9% |
| Next report (est.)2026-08-01 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$45.1M |
| Earnings (TTM)-$43.6M |
| ROE−61.5% |
| Net margin−133.4% |
| Sales growth 3Y10.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+68.3% |
| 1Y+45.8% |
| 3Y−60.0% |
| 5Y−97.7% |
| Since incept. (ann.)−44.5% |
Total return through 2026-07-30 · series begins 2019-03-28. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)70.6% |
| Ann. volatility (3Y)77.5% |
| Sharpe (1Y)0.87 |
| Sharpe (3Y)−0.02 |
| Max drawdown (1Y)−58.5% |
| Max drawdown (3Y)−80.8% |
| Beta (3Y vs SPY)2.00 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 2.2M | $12M | 9.05% | +16.6% |
| Aberdeen Group plc | 2.2M | $12M | 9.02% | +4.3% |
| Empery Asset Management, LP | 2.0M | $11M | 7.96% | −10.3% |
| Bleichroeder LP | 1.7M | $9M | 6.72% | +0.0% |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.1M | $6M | 4.31% | +0.0% |
| Driehaus Capital Management LLC | 995,371 | $5M | 4.03% | +26.4% |
| Lynx1 Capital Management LP | 985,113 | $5M | 3.98% | −0.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 910,740 | $5M | 3.68% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.75 | — | $10.8M | +37272.4% |
| 2025-12-31 | 2026-03-12 | — | — | $34.2M | +5261.1% |
| 2025-09-30 | 2025-11-03 | −$1.84 | — | $13,000 | −97.7% |
| 2025-06-30 | 2025-08-07 | −$2.13 | −145.6% | $18,000 | −100.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-01 is ESTIMATED from filing cadence (median gap 88d) — not company-confirmed.
Operating 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
